Publications by authors named "K Pavlakis"
Determination of microsatellite instability (MSI)/mismatch repair (MMR) status in cancer has several clinical implications. Our aim was to integrate MSI/MMR status from patients tested in Greece to assess the prevalence of MSI-high (MSI-H)/deficient MMR (dMMR) per tumor type, testing patterns over time and concordance between MSI and MMR status. We retrospectively recorded MSI/MMR testing data of patients with diverse tumor types performed in pathology and molecular diagnostics laboratories across Greece.
View Article and Find Full Text PDFTwo rare cases of benign struma ovarii with malignant recurrence.
Endocrinol Diabetes Metab Case Rep
April 2024
Article Synopsis
- - Struma ovarii is a type of ovarian teratoma found in 2-5% of cases, and malignant transformation is rare (<5%), with two cases presented where benign struma ovarii evolved into highly differentiated follicular carcinoma of the ovary (HDFCO) years later.
- - The first case involved a 37-year-old woman who had multiple metastases after being previously diagnosed with benign struma ovarii 14 years ago, while the second case was a 26-year-old woman whose condition re-emerged 4 years after a benign diagnosis.
- - Both patients underwent surgery along with total thyroidectomy and radioactive iodine therapy, highlighting the challenges in diagnosing HDFCO due to its histological similarities
SMARCA4 (BRG1) and SMARCA2 (BRM) are the two paralogous ATPases of the SWI/SNF chromatin remodeling complexes frequently inactivated in cancers. Cells deficient in either ATPase have been shown to depend on the remaining counterpart for survival. Contrary to this paralog synthetic lethality, concomitant loss of SMARCA4/2 occurs in a subset of cancers associated with very poor outcomes.
View Article and Find Full Text PDFBackground: The standard surgical treatment of endometrial carcinoma (EC) consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in EC in a multidisciplinary setting. While also addressing work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility sparing treatment.
View Article and Find Full Text PDFStudy Question: How should fertility-sparing treatment of patients with endometrial carcinoma be performed?
Summary Answer: Forty-eight recommendations were formulated on fertility-sparing treatment of patients with endometrial carcinoma.
What Is Known Already: The standard surgical treatment of endometrial carcinoma consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in endometrial carcinoma in a multidisciplinary setting.